Drug Database
ST

streptokinase (Heberkinase)

✓ Approved

YM BioSciences Inc. · PLG · Recombinant Proteins

What is streptokinase?

streptokinase is a recombinant proteins developed by YM BioSciences Inc.. It is approved for therapeutic indications via injectable (others) or intravenous (iv).

Drug Profile

Brand NamesHeberkinase
CompanyYM BioSciences Inc.
Drug ClassRecombinant Proteins
Molecular TargetPLG
RouteInjectable (Others), Intravenous (IV)
StatusApproved
Sources: ClinicalTrials.gov, YM BioSciences Inc.

Mechanism of Action

Molecular Targets

streptokinase acts on 1 molecular target:

PLGplasminogen (HAE4)
Want deeper analysis?Noah AI can explain complex mechanisms and compare to similar drugs.

Therapeutic Indications

streptokinase is developed for 1 unique indication across 1 therapeutic area.

Therapeutic AreaConditionPhase
Cardiac disordersMyocardial infarction✓ Approved

Related Research Articles

PubMedJournal of the American Society for Mass Spectrometry2026-05-01

Metabolomic Characterization of Streptococcus dysgalactiae subsp. equisimilis: Different Metabolic States in Planktonic and Biofilm Forms and the Influence of Streptokinase.

Rockstroh Jan J, Pagel Anna-Johanna AJ, Neufend Janine V JV, Siemens Nikolai N et al.

Despite the extensive research that has been conducted into the metabolism of Gram-positive bacteria, relatively little is known about the adaptations of Streptococcus dysgalactiae subsp. equisimilis (SDSE) during biofilm maturation. This study uses targeted metabolomics and MALDI MS imaging to investigate time-dependent changes in the metabolome composition. Key metabolites of energy metabolism were quantified in planktonic and biofilm bacteria. A distinct decline in the abundance of metabolites from all analyzed metabolic pathways was observed in sessile SDSE. Furthermore, we observed a broad decrease of nutrient utilization in biofilm-associated bacteria. Additionally, we examined the impact of deleting streptokinase on SDSE metabolism. Especially, concentrations of glycolysis intermediates and adenosine phosphates exhibited significant alterations when comparing the S118 strain with its mutant. The absence of the ska gene led to drastic changes in both energy and structural metabolism. These findings provide new insight into the metabolic adaptations of SDSE and represent an initial step toward understanding its role in pathogenesis.

PMID 42062893
Read full article →
PubMedIndian pediatrics2026-04-27

Clinical Practices for Management of Empyema Thoracis in Children: A Survey of Pediatricians in India.

Mathew Joseph L JL, Chandrasekaran Venkatesh V, Kumar Ketan K, Kaur Satnam S et al.

This survey was conducted to explore the current status of empyema thoracis management practices of pediatricians in India, as a prelude to developing evidence-based guidelines for managing empyema. A questionnaire examining various aspects of empyema management (diagnosis, investigations, treatment, monitoring and follow-up) was prepared, refined, and pilot-tested. It was disseminated to pediatricians across the country, through a Google form link, using email and a social media platform. Responses were collated, analyzed, and presented with descriptive statistics. Ninety-four complete responses were received, mostly from pediatricians in teaching/ tertiary-care hospitals. There were significant variations in all aspects of empyema management. There was overuse of computed tomography (CT) scan (27%) and pleural fluid Cartridge Based Nucleic Acid Amplification Test (CBNAAT) (61%) in children with pleural effusion. Whilst > 80% pediatricians used ceftriaxone empirically for pneumonia and empyema, co-amoxiclav (18%), vancomycin (56%), and teicoplanin or linezolid (16%) were also used for empyema. Less than three quarters of respondents used intercostal drainage appropriately. 25% pediatricians routinely used intrapleural fibrinolytic therapy (most often streptokinase); 37% did not use it at all. The common indications were septations/loculations on ultrasonography (57%), thick pus (38%), and persisting clinical features (33%). The duration of antibiotics ranged from < 4 weeks (18%), 4-6 weeks (59%), and > 6 weeks (15%). The indications for surgical referral also varied widely, as did monitoring during therapy, and post-treatment follow-up protocols. There are significant variations in all facets of empyema management amongst pediatricians working in diverse Indian healthcare settings, underscoring the need for evidence-based guideline recommendations.

PMID 42043772
Read full article →
PubMedKathmandu University medical journal (KUMJ)2026-04-24

Reversing AV Block and Cardiogenic Shock in STEMI Care: A Case Report on Use of Fibrinolysis and Inotrope without PCI in Rural Nepal.

Pradhan A A, Tamrakar P P, Bhandari J J, Mahat P P

Atrioventricular block and cardiogenic shock are critical complications of inferior wall myocardial infarction with high mortality, especially in resource-limited settings lacking percutaneous coronary intervention. We report a 53-year-old male smoker presenting to a rural hospital with acute chest pain, dyspnea, and profound hemodynamic instability with electrocardiogram showing inferior wall ST-segment elevation myocardial infarction with Mobitz type I atrioventricular block. This case highlights reversal of atrioventricular block with return of hemodynamic stablility using Streptokinase and ionotropes in a rural setting. Therefore, timely fibrinolysis and inotropes in managing inferior wall myocardial infarction with atrioventricular block and cardiogenic shock in percutaneous coronary intervention -inaccessible regions and strengthening rural ST segment elevation myocardial infarction care networks is crucial.

PMID 42028780
Read full article →
PubMedAnimal models and experimental medicine2026-04-13

Pharmacological evaluation of Adenostemma lavenia acetone extract in Swiss Albino mice: Analgesic, anti-inflammatory, and thrombolytic insights from in vivo, in vitro, density functional theory, and molecular docking studies.

Moon Nusrat Jahan NJ, Mohammad Mahathir M, Mamun Md Jahirul Islam MJI, Nova Fahmina Binty Azim FBA et al.

Adenostemma lavenia, a plant long used in traditional medicine to manage pain, inflammation, and circulatory disorders, has not been thoroughly validated using modern scientific methods. This study presents the first comprehensive investigation into the analgesic, anti-inflammatory, and thrombolytic potentials of the acetone extract of A. lavenia leaves (AEAL), employing an integrated strategy that combines in vivo, in vitro, and in silico methodologies. The analgesic effects of the extract AEAL were evaluated in mice (five mice per group) using acetic acid-induced writhing, formalin-induced pain, and hot plate tests. Anti-inflammatory activity was assessed through xylene-induced ear edema in mice, heat-induced hemolysis of human red blood cells (HRBC), and protein denaturation assays. In vitro clot lysis was performed in triplicate to determine the thrombolytic activity of AEAL and a standard streptokinase. Molecular docking, density functional theory (DFT), and ADME/T profiling were conducted to identify and evaluate potential bioactive compounds. AEAL demonstrated significant, dose-dependent analgesic effects, reducing writhing responses by 53.74% (at 400 mg/kg), and inhibiting formalin-induced pain by up to 65.76% (p < 0.01). It also showed potent anti-inflammatory activity, with edema inhibition of 55.17% at a 400 mg/kg dose (p < 0.001), HRBC membrane stabilization (77.19%), and 85.96% suppression of protein denaturation. In thrombolytic testing, AEAL significantly (p < 0.001) achieved 68.1% clot dissolution compared with the control group. In silico analysis revealed that sesquiphellandrene strongly bound to COX-2 (-7.7 kcal/mol) and tissue plasminogen activator (tPA) (-6.9 kcal/mol), whereas derivatives of 2,3-hexadienoic acid exhibited notable COX-2 inhibition (-7.4 kcal/mol). ADMET predictions indicated favorable drug-like properties. In the DFT analysis, sesquiphellandrene and 2,3-hexadienoic acid, 2-methyl-4-phenyl-, methyl ester exhibited a narrow HOMO-LUMO energy gap, indicating high chemical reactivity and a greater propensity for electron-transfer processes. The AEAL exhibits robust analgesic, anti-inflammatory, and thrombolytic activities, corroborated by computational analysis of its phytoconstituents. These results validate its ethnopharmacological use and highlight sesquiphellandrene as a promising candidate for future therapeutic development. Further isolation, mechanistic studies, and preclinical evaluation of sesquiphellandrene are warranted to harness its full pharmacological potential.

PMID 41968572
Read full article →
PubMedGut microbes reports2026-03-30

The living medicine inside us: in vitro therapeutic prospects of human gut bacteria.

Andalib K M Salim KMS, Rodosy Fabliha Bashashat FB, Habib Ahsan A

Gut microbial metabolism is intimately coupled to host health and disease. Recent knowledge on potential health benefits of gut microbiome lays the groundwork for development of novel therapeutic strategies. But how microbiota-derived metabolites impact on host-microbiome crosstalk remains untapped from therapeutic perspectives. In this study, six gut bacteria sourced from a fecal pool of forty healthy donors were cultured in three distinct growth media. Subsequently, the bacteria were identified through 16S rRNA gene sequencing and subjected to metabolite extraction to evaluate their anti-microbial, anti-oxidant and anti-thrombotic potential. Findings reveal strong anti-oxidant activities in the metabolic-extracts from all the isolates. Metabolites derived from Lactobacillus rhamnosus, Priestia flexa and Bacillus subtiilis inhibited the growth of clinically pathogenic strains Escherichia coli ATCC-8739, Salmonella typhi ATCC-1408 and Staphylococcus aureus ATCC-6538. Escherichia fergusonii originated metabolites demonstrated the highest efficacy in lysing blood clots compared to streptokinase. Additionally, extracts from all the isolates exhibited significant ability to delay coagulation time, competing with standard warfarin. Thus, the findings of our early-stage study provide novel insights into metabolomic functions of gut microbiota. This study underscores the significance of exploring these active metabolites for prospective therapeutic and clinical exploration at the intersection of drug discovery and live bio-therapeutics.

PMID 41909902
Read full article →
PubMedThe American journal of medicine2026-03-22

Association of serum albumin level with bleeding event in patients with venous thromboembolism treated with oral anticoagulants.

Yoshioka Goro G, Tanaka Atsushi A, Natsuaki Masahiro M, Goriki Yuhei Y et al.

Association between serum albumin levels and bleeding events in patients with venous thromboembolism was unclear. In this Japanese multi-center registry, we enrolled 993 consecutive patients diagnosed with acute venous thromboembolism and treated with anticoagulants between 2015 and 2024, where 732 patients were finally analysed. The primary outcome was 180-day bleeding events, defined as moderate or severe bleeding according to the Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries criteria. The effect of serum albumin level on the outcome was determined using a multivariate Cox proportional hazard regression model adjusted for conventional bleeding risk scoring systems. The mean age was 68.6 ± 14.5 years, and 37.2% were men. In total, 38.4% had concomitant active cancer, 6% had a previous history of venous thromboembolism, and 90% were treated with direct oral anticoagulants. The primary outcome occurred in 36 patients (5%), and serum albumin level was significantly lower in the event group than in the event-free group (2.9 ± 0.7 g/dL versus. 3.2 ± 0.7 g/dL, P = 0.014). In multivariate Cox proportional risk analysis, serum albumin level was independently associated with the outcome (adjusted hazard ratio 1.77, per 1 g/dL decrease; 95% confidence interval, 1.12-2.75; P = 0.013). This was consistent in patients with active cancer (adjusted hazard ratio 2.15, per 1 g/dL decrease; 95% confidence interval, 1.29-3.57; P = 0.003), but not in patients without it. Decreased serum albumin levels were associated with 180-day bleeding events in patients with venous thromboembolism treated with anticoagulants, especially in those with concomitant active cancer.

PMID 41864403
Read full article →

+7163 more articles available with a free account

Sign up free to view all articles →

Ask about streptokinase